key: cord-1030469-zy7md3gr authors: Soleimani, Reza; Deckers, Corentin; Huang, Te‐Din; Bogaerts, Pierre; Evrard, Stéphanie; Wallemme, Isaline; Habib, Boutaina; Rouzé, Pauline; Denis, Olivier title: Rapid COVID‐19 antigenic tests: Usefulness of a modified method for diagnosis date: 2021-05-31 journal: J Med Virol DOI: 10.1002/jmv.27094 sha: 4b6ea05712cd23c99c888d864bd8dff1fd19e942 doc_id: 1030469 cord_uid: zy7md3gr The current reliable recommended test for coronavirus disease 2019 (COVID‐19) diagnosis is quantitative reverse‐transcription polymerase chain reaction (RT‐qPCR). Rapid antigen test devices could be useful as they are less expensive, faster without the need of specialized laboratories to perform the test. We report the performances of two rapid immunochromatographic antigen testing devices compared with RT‐qPCR for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) detection in nasopharyngeal samples. We carried out a lateral‐flow tests study on 401 nasopharyngeal swab samples from nonduplicated suspected COVID‐19 subjects. An equal volume of universal transport medium tubes‐containing samples (dilution ratio = 1:15) were added to the manufacturer's extraction buffer solution (dilution ratio = 1:2) and analyzed on BioSpeedia COVID19Speed‐Antigen Test and on Abbott Panbio™ COVID‐19 Ag Rapid Test, devices. Qualitative results were compared to those obtained by the RT‐qPCR (Allplex™ SARS‐CoV‐2 Assay Seegene). Based on our data, the overall sensitivity for BioSpeedia and Panbio devices was estimated at 65.5% and 75.0%, respectively. The sensitivity was greater for cycle threshold values less than 25 achieving 90.4 and 96.8 for BioSpeedia and Panbio devices, respectively. A perfect specificity of 100.0% was observed for both devices. Selected samples were tested on BS and PB devices, two CE-IVD devices before the RT-qPCR routine assay. All tests were immediately performed after sampling. The principle of both tests was similar. Briefly, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen would react with gold-conjugated antibody and form an immune complex that will migrate and be captured by an- The COVID-19 diagnosis was confirmed by using the coronavirus Allplex™ SARS-CoV-2 Assay (Seegene Inc.) on the nasopharyngeal swab samples in UTM targeting the RNA-dependent RNA polymerase (RdRp)/Spike (S), Envelope (E), and Nucleocapsid (N) genes. The extraction of the viral RNA was carried out on the Seegene STAR LET and the amplification was performed on the CFX 96 thermal cycler (BioRad). The amplification parameters were as follow: 20 min at 50°C for reverse transcription, 15 min at 95°C for activation, followed by 44 cycles of 15 s at 94°C, and 30 s at 58°C. A cycle threshold value less than 39 for the four genes, was defined as a positive test. 2, 7 We calculated the means of Ct value as the main quantitative reference results and to classify positive samples into high (Ct < 25), moderate (Ct ≥ 25 and < 30) and low (Ct ≥ 30) viral load groups. A result with Ct value ≥ 39 was considered as a negative. Means and 95% CIs, median and interquartile rates were determined in obtained results. The agreement between the methods was determined by the kappa index. A p < 0.05 was considered as statistically significant. Data analysis was performed using GraphPad Prism software (Version 8.0). showed Ct values < 30, BioSpeedia cassette detected 152 samples and 174 were correctly classified using Panbio device. The sensitivity and specificity were defined as the percentage of true positive and true negative results correctly identified by devices, respectively. The PPV and NPV were defined as the probability of positive and negative results among true patients and healthy volunteers, respectively. Accuracy was defined as the closeness of the obtained results to an expected value. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID-19 patients Field evaluation of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres Comparison of rapid antigen tests for COVID-19 Mass screening vs lockdown vs combination of both to control COVID-19: a systematic review Designing Clinical Research Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in communitydwelling subjects with symptoms of potential SARS-CoV-2 infection Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms Head-to-head comparison of rapid and automated antigen detection tests for the diagnosis of SARS-CoV-2 infection https://orcid.org/0000-0003-3618-668X Additional Supporting Information may be found online in the supporting information tab for this article.